NCT04022980View on ClinicalTrials.gov

Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

January 21, 2025

Study Completion Date

December 31, 2025

Conditions
Brain and Nervous SystemEye and Orbit
Interventions
DRUG

Nivolumab

HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.

Trial Locations (4)

27514

UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill

28204

Levine Cancer Institute, Charlotte

77030

The University of Texas - MD Anderson Cancer Center, Houston

02215

Dana Farber Cancer Institute, Brookline

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Atrium Health Levine Cancer Institute

OTHER

lead

Wake Forest University Health Sciences

OTHER